Tremeau Pharmaceuticals to Host a Key Opinion Leader Webinar on Rofecoxib in Migraine Management on Tuesday, October 25
CONCORD, Mass., October 20, 2022–(BUSINESS WIRE)–Tremeau Pharmaceuticals today announced that it will host a Key Opinion Leader (KOL) webinar to discuss the unmet medical need in migraine management and the potential role of rofecoxib, a COX-2 selective nonsteroidal anti-inflammatory drug. inflammatory drug (NSAIDs), in the treatment landscape on Tuesday, October 25, 2022 at 11:00 a.m. …